NeuroVive appoints Mark Farmery as Vice President Business Development

Lund, Sweden, September 1, 2017 - NeuroVive Pharmaceutical AB (“NeuroVive” or “the company”, Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced the appointment of Mark Farmery (PhD) as Vice President Business Development. Dr Farmery will report to CEO Erik Kinnman and will join the company’s management team.

The appointment of Dr Farmery strengthens and expands the team in a critical area and is in line with NeuroVive’s dual business model, which focuses on early phase projects for out-licensing at the pre-clinical stage and the acquisition and development of orphan drug projects all the way to the market. Dr Farmery’s initial focus will be to lead out-licensing activities around NeuroVive’s lead compound NV556 for NASH.

Moreover, NeuroVive operates a networked partnership organisational model to advance specific projects, which includes the company’s genetic mitochondrial disease project KL1333, recently in-licensed from Yungjin Pharm. A central part of Dr Farmery’s role will be to ensure high quality alliance management in relation to this and similar projects.

Dr Farmery is a senior executive focused on biopharma business development, with more than 16 years’ experience in asset scouting and evaluation, negotiation and project and alliance management. He has an extensive deal-making track record across pharma, biotech and academia in multiple therapeutic areas.

Prior to joining NeuroVive, Dr Farmery has held various business development positions at Karolinska Institutet Innovations AB, AstraZeneca and Karo Bio AB. He has also managed research teams and led specific projects in the fields of Alzheimer’s disease modification and protein modification and misfolding at Karolinska Institutet and the Universities of Gothenburg and Manchester. Dr Farmery received his BSc in Biomedical Sciences (Microbiology) from the University of Bradford, UK, and his PhD in Biochemistry and Molecular Microbiology from the University of Leeds, UK.

“I am thrilled to join NeuroVive. It is a unique possibility for me to work with the company’s clinical and late stage research programs in areas ranging from genetic mitochondrial disorders and traumatic brain injury, to cancer and metabolic diseases such as NASH”, commented Mark Farmery.

“It gives me great pleasure to welcome Mark to the company. His knowledge and expertise will be tremendously valuable to NeuroVive when we now enter a new exciting phase of the company. In the new capacity as head of business development Mark will be very important in the development of our company”, said Erik Kinnman, CEO of NeuroVive.

For further information, please contact:

Erik Kinnman, CEO NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)

Medicon Village, SE-223 81 Lund, Sweden

Tel: +46 (0)46 275 62 20 (switchboard)

www.neurovive.com

About NeuroVive

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). 

About Us

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). www.neurovive.com

Subscribe

Media

Media

Documents & Links